ArticleCurrent oncology (Toronto, Ont.)2006
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.
Article in Current oncology (Toronto, Ont.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.World journal of gastroenterology · 2015Guideline
- Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.European journal of cancer care · 2013Pooled it
- Endoscopic mucosal resection with circumferential incision for treatment of rectal carcinoid tumours.World journal of surgical oncology · 2014Trial
- Article
- A Rare Discovery of Neuroendocrine Tumor: Cardiac Mass.Journal of community hospital internal medicine perspectives · 2025Article
- Article
- Differential to Terminal Ileitis: Terminal Ileum Neuroendocrine Tumor Identified on Screening Colonoscopy.Ochsner journal · 2023Article
- Carcinoid Tumors: from the Past into the Future.Maedica · 2021Article
- Primary neuroendocrine tumours of the heart: case report and literature review.BMJ case reports · 2021Article
- Flushing: A Diagnostic Dilemma.Cureus · 2021Article
- Carcinoid Syndrome: A Review.Cureus · 2020Review
- Robotic-assisted laparoscopic resection of a primary renal neuroendocrine carcinoma.BMJ case reports · 2019Article
- Pulmonary carcinoid presenting with persistent pneumothorax.BMJ case reports · 2019Article
- Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.Cancer management and research · 2019Review
- Clinical outcomes of ligation-assisted endoscopic resection for duodenal neuroendocrine tumors.Medicine · 2018Observational
- Primary Carcinoid Tumor of the Testis: A Case Report and Review of the Literature.Case reports in urology · 2018Article
- Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.Neoplasia (New York, N.Y.) · 2017Review
- Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.Cancer gene therapy · 2015Article
- Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.Current oncology (Toronto, Ont.) · 2015Article
- Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with review of the literature.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoid tumours are relatively rare and, in general, slow growing. They can be "non-functioning" tumours, presenting as a tumour mass, or "functioning" tumours secondary to the production of several biopeptides leading to the carcinoid syndrome. Though these tumours represent 0.25% of an oncology practice, a proper understanding of the clinical course of the disease and of the importance of appropriate diagnostic and therapeutic measures is very important. Proper patient management can lead to cure, particularly if the tumour can be fully resected, or to long-term palliation with medical treatment or cytoreductive surgery, or both, with significant prolongation of survival. A good understanding of the use of somatostatin analogues to achieve effective symptomatic control and of the importance of adequate follow-up and cardiac monitoring to prevent or effectively treat cardiac complications can contribute significantly to optimal control of this complex disease, ultimately improving the quality of life of affected patients. This article, developed by a group of Canadian experts, provides a framework that will assist clinicians in taking an optimal approach to managing their patients with carcinoid tumour.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.